About ABK Biomedical
ABK Biomedical is a Healthcare company based in Halifax (Canada) founded in 2012. Imageable embolic devices are developed for hypervascular tumors. ABK Biomedical has raised $139.93 million across 7 funding rounds from investors including J P Morgan, Varian and Eight Roads Ventures. The company has 49 employees. ABK Biomedical offers products and services including Eye90 microspheres and Easi-Vue embolic microspheres. Its focus areas include Life Sciences, Oncology, Medical Devices and Therapies. Its legal entity is ABK.
Company details
ABK Biomedical was founded in 2012 in Halifax, Canada, within the biomedical sector. Embolic medical devices are developed for treating benign and malignant hypervascular tumors. Eye90 microspheres, designed for Y-90 radioembolization, are used in liver tumor therapy and enable CT imaging for dosimetry. Easi-Vue embolic microspheres are provided for bland embolization, allowing visualization at target sites. Operations focus on device innovation for oncology applications.
- Headquarters Halifax, Canada
- Employees 49
- SectorsHealthcare
- Email••••••••
- Website abkbiomedical.com
- Social LinkedIn X
- Legal Name Abk
- Total Equity Funding$139.93M (USD)
in 7 rounds
- Latest Funding Round$35M (USD), Series D
Oct 2025
- InvestorsJ P Morgan
& 6 more
- Employee Count49
Products & Services of ABK Biomedical
ABK Biomedical offers a comprehensive portfolio of products and services, including Eye90 microspheres and Easi-Vue embolic microspheres.
Y90 radioembolization device for liver cancer treatment
Product for embolization of tumors and malformations
Funding Insights of ABK Biomedical
ABK Biomedical has successfully raised a total of $139.93M across 7 strategic funding rounds. The most recent funding activity was a Series D round of $35 million completed in October 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $139.93M
- Total Rounds 7
- Last Round Series D — $35M
- First Round $750,000
(Oct 2012)
- Investors Count 7
All 7 funding rounds of ABK Biomedical with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2025 | $35M | Series D | – | J P Morgan | |
| Apr 2025 | $26.09M | Series C | – | – | – |
| Dec 2022 | $30M | Series C | – | Sante | |
| Sep 2022 | $18.09M | Series B | – | – | – |
| Apr 2019 | $30M | Series B | – | F-Prime Capital, Varian Medical Systems | – |
| Oct 2012 | $750,000 | Seed | – | – | |
| Oct 2012 | $500,000 | Debt – Conventional | – | – |
7 investors in total: 7 institutional.
Investors in ABK Biomedical
ABK Biomedical has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include J P Morgan, Varian and Eight Roads Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Santé is engaged in healthcare and technology investment management. | 2017 | sante.com | Minneapolis, United States | |
Investments in life sciences, technology, healthtech, and crypto sectors from global locations. | fprimecapital.com | |||
Venture capital investment and global platform support for startups. | 2008 | eightroads.com | London, United Kingdom | |
Varian is focused on developing cancer treatment technologies. | 1948 | varian.com | Palo Alto, United States | |
Delivers expert business strategy and technology consulting services to support organizational growth. | 2009 | investnovascotia.ca | Halifax, Canada | |
Economic development in Atlantic Canada is facilitated by this agency. | acoa.ca | Canada | ||
Comprehensive financial services are provided to corporations and individuals. | 1799 | jpmorgan.com | New York, United States |
Investor details for ABK Biomedical
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of ABK Biomedical
15 people are tracked at ABK Biomedical (12 in leadership, 3 in team); the tracked headcount is 49.
| Name | Role | Group |
|---|---|---|
Caitlin Slaunwhite | Director Of Quality Assurance | Leadership |
Michael Mangano | President and CEO | Leadership |
Aravind Arepally | Chief Medical Officer | Leadership |
Gary Donofrio | Chief Business Officer | Leadership |
Marco Bonilla | Director, Product and Program Management | Leadership |
Mike Tyson | CFO | Leadership |
Marc Gregoire | Vice President of R&D and Nuclear Operations | Leadership |
Kurt van Vulpen | Director Of Operations | Leadership |
Brandi Woods | Sr. Director Regulatory Affairs | Leadership |
Nikki McGuire | Director, Clinical Operations | Leadership |
Amit V. | Sr. Director, Clincial Development | Leadership |
David Dobrowski | Vice President Clinical Development & Regulatory Affairs | Leadership |
Robert Tersigni | Financial Controller | Team |
Anthony Headley | Svp, Manufacturing, R&d, And Engineering | Team |
Cathy Whitman | Principal Scientist, QA | Team |
Complete people profiles for ABK Biomedical
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of ABK Biomedical
3 dated milestones of ABK Biomedical across 13 years, from founding to its latest funding, stage changes and deals.
- Founded ABK Biomedical is founded.
- Funding First funding round of $750K.
- Funding Latest funding round, Series D, of $35.0M.
Web traffic of ABK Biomedical
The website of ABK Biomedical (abkbiomedical.com) receives about 3.3K visits a month.
- Monthly visits3.3K
▼ 8.3% vs previous month
Websites whose visitors overlap most with ABK Biomedical. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| smartsti.com | 100% | 9.1K | #2,549,143 | View details | |
| appilitherapeutics.com | 98% | 2.8K | #6,177,068 | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Abk Biomedical
Complete news archive for ABK Biomedical
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ABK Biomedical
ABK Biomedical was founded in 2012.
ABK Biomedical is headquartered in Halifax, Canada. It is registered at Halifax, Nova Scotia, Canada.
ABK Biomedical is a funded company, having raised a total of $139.93M across 7 funding rounds to date. The company's 1st funding round was a Seed of $750K, raised on Oct 2012.
ABK Biomedical has 49 employees.
ABK Biomedical was founded in 2012 in Halifax, Canada, within the biomedical sector. Embolic medical devices are developed for treating benign and malignant hypervascular tumors. Eye90 microspheres, designed for Y-90 radioembolization, are used in liver tumor therapy and enable CT imaging for dosimetry. Easi-Vue embolic microspheres are provided for bland embolization, allowing visualization at target sites. Operations focus on device innovation for oncology applications.
ABK Biomedical offers Eye90 microspheres and Easi-Vue embolic microspheres.
ABK Biomedical has 7 investors. Key investors include J P Morgan, Varian, Eight Roads Ventures, Santé, and F-Prime Capital.
ABK Biomedical operates through Abk.